"The voice for cancer physicians and their patients in Massachusetts."

FDA granted accelerated approval to tazemetostat (Tazverik)

27 Feb 2020 9:19 AM | Anonymous

The U.S. Food and Drug Administration granted accelerated approval to tazemetostat (Tazverik; Epizyme) for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Read full press release.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software